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catheter and your catheter takes up 50% of the lumen, I don’t know
what that pressure drop means past the catheter.
Dr Andros. Do you use the pressure wire?
Dr Ahn. That is a good suggestion. I had not used the
pressure wire. The cardiologists use that routinely, and it is also
very expensive, I might add. I’m not sure our hospital would look
favorably on that.
As far as characterization of the lesions, the tissue loss and
gangrene are obvious. I mean I don’t need to show you a picture of
that. Everyone in the room knows what gangrene and tissue loss is.
The ischemic rest pain is a little slippery slope, as you said, but these
were all patients—if they had ischemic rest pain, I think I know
after 20 years of practice, I think I know what ischemic rest pain is,
and I’ll now define that for the audience again. Patients with
dependent rubor and pallor on elevation who have dependent-
related ischemia worse at night and better when they hang their
foot over the edge associated with hemodynamic pressure mea-
surements or toe pressures, especially in diabetics, that corresponds
to the ischemic pain. I think my definition of ischemic rest pain is
pretty strict and very comparable to what most of the people in the
audience would use as well.
Dr Larry Kraiss (Salt Lake City, Utah). Nice paper, Sam, but I
think this is a paper that is begging for a comparisongroupor a control
group, and I would ask what you think the results would be if you
took your surgical patients and performed the same kind of analysis
that you have shown us with your interventional treated patients.
The second thing I would ask is, I share your opinion that
there is a difference between patients with tissue loss and rest pain,
but I would argue that the patient with rest pain actually needs a
more durable result perhaps than the patient with tissue loss, and
so I want to know if you approach those patients differently in
terms of your initial decision making.
Dr Ahn. That is a very good question, and I certainly agree
with you and thank you for that suggestion, because you are right.
We do not have a control group, and based on your suggestions, I
will go back and look at the 58 patients that we excluded, look at
them and compare to see how the open group did compared to
this. But nomatter what I do, this is a retrospective study, and what
you are really implying is that we need to do a good prospective
randomized trial. Now, Sam Wilson actually did that and reported
it back about 10 years ago in a VA population and showed that
there was no statistically significant difference between the open
bypass vs the endovascular PTA group in patients with infraingui-
nal lesions. For iliac lesions there was a slightly better improvement
in the open bypass, but it was only about a 10% difference.
Regarding your comments about the rest pain vs tissue loss,
the rest pain patients can often be treated by just improving one
level of occlusion. You don’t need to get a perfect–most of these
patients have multilevel disease. For tissue loss, you need to im-
prove at least two, maybe three, and get good flow down to the
foot, but for rest pain if you just take care of one level you will get
them out of that rest pain, so oftentimes in these patients if you just
take care of the inflow, say just the iliacs plus or minus the
profunda, you don’t need to do their SFA and tibials all the time to
get them out of the rest pain. For rest pain, you do not have to get
them perfect.
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The role of endoluminal therapy in the treatment of peripheral
arterial disease is dramatically expanding.1 Skeptics of endovascular
therapy oft opine that PTA [percutaneous transluminal angio-
plasty] works best for those least in need of intervention, thus
suggesting that PTA is reasonable for claudicants with focal lesions
but has little to offer patients with critical limb ischemia (CLI).
Ahn et al report a 10-year experience with a cohort of CLI patients
managed by endoluminal therapy. Over the study period, 111
patients (128 limbs; 63% of total) with CLI were treated by PTA
alone, whereas 76 limbs (37%) required open surgery. Technical
success was 96%, clinical success was 93%, 30-day mortality was
0.9%, and long-term limb salvage was 89%. At first glance, these
results in CLI patients after PTA are quite comparable to those of
open surgery and seem astonishing. However, the devil is in the
details.
The mean follow-up was short (14.7 months) and likely
reflected not only a shift toward less invasive approaches in recent
practice, but also the sobering reality that patients with CLI do not
live long (5-year series mortality of 56%). Many malignancies have
superior survival rates. In addition, 45% of patients had rest pain
without tissue loss, and 33% required only iliac PTA. It is no
surprise that PTA for hemodynamic iliac lesions often resolves
ischemic rest pain. Results were predictably worse in patients with
tissue loss and multiple, distal, or TransAtlantic Inter-Society
Consensus D lesions. Primary patency was low (31% at 5 years),
but secondary patency was 76%; this implies the necessity for
reintervention. The authors do not provide the frequency, mor-
bidity, or costs of repeat interventions. Primary patency, however,
may not be the ultimate objective of CLI treatment. A 5-year
clinical improvement rate (defined by Society of Vascular Surgery
category) of 80% and a 6-year limb salvage rate of 89% are more
meaningful end points.
What are the implications of this report? First, it is imperative
that vascular surgeons become facile with thrombolysis, conven-
tional PTA, subintimal angioplasty, newer technologies such as
cutting balloons, and stent placement. These evolving therapies are
applicable to an increasing percentage of our patients. Second,
treatment outcomes require redefinition. Long-term patency
should not be the Holy Grail of outcome assessment, particularly
for CLI, in which symptom relief, lesion healing, and limb salvage,
withminimal morbidity, aremore critical end points. Open surgery
offers excellent patency rates, but morbidity is significant.2 Finally,
it is clear that as the proportion of peripheral arterial disease
patients effectively treated by endoluminal therapy expands, the
numbers of open cases for practicing vascular surgeons and resi-
dent trainees will continue to wane. A recent report identified the
difficulty in providing adequate numbers of open distal reconstruc-
tions for vascular surgical trainees because of the shift toward
subintimal angioplasty.3 New clinical training paradigms for resi-
dents and changes in the residency review committee case volume
and distribution (open vs PTA) requirements will need to be
rapidly implemented. Although there will be a role for tibial
bypasses and complex, open reconstructions for the foreseeable
future, “admit that the waters, around you have grown . . . for the
times they are a changin’.”4
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